IBDEI3I7 ; ; 19-NOV-2015
;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
Q:'DIFQR(358.4) F I=1:2 S X=$T(Q+I) Q:X="" S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E S @X=Y
Q Q
;;^UTILITY(U,$J,358.4,751,0)
;;=INTRAVITREAL INJECTIONS^3^79
;;^UTILITY(U,$J,358.4,752,0)
;;=EDUCATION/COUNSELING^1^79
;;^UTILITY(U,$J,358.4,753,0)
;;=ANTERIOR SEGMENT^2^80
;;^UTILITY(U,$J,358.4,754,0)
;;=GLAUCOMA^4^80
;;^UTILITY(U,$J,358.4,755,0)
;;=INFECTIONS^5^80
;;^UTILITY(U,$J,358.4,756,0)
;;=LENS/CATARACT^6^80
;;^UTILITY(U,$J,358.4,757,0)
;;=LOW VISION/BLINDNESS^7^80
;;^UTILITY(U,$J,358.4,758,0)
;;=DIABETES^3^80
;;^UTILITY(U,$J,358.4,759,0)
;;=MOST COMMON & POST OP^1^80
;;^UTILITY(U,$J,358.4,760,0)
;;=NEUROLOGIC EYE DISEASE^8^80
;;^UTILITY(U,$J,358.4,761,0)
;;=ORBIT/EYELID/LACRIMAL^9^80
;;^UTILITY(U,$J,358.4,762,0)
;;=REFRACTION^10^80
;;^UTILITY(U,$J,358.4,763,0)
;;=RETINA/VITREOUS^11^80
;;^UTILITY(U,$J,358.4,764,0)
;;=STRABISMUS^12^80
;;^UTILITY(U,$J,358.4,765,0)
;;=SYSTEMIC/TRAUMA/OTHER^13^80
;;^UTILITY(U,$J,358.4,766,0)
;;=REFRACTION^1^81
;;^UTILITY(U,$J,358.4,767,0)
;;=GLASSES/CONTACT LENSES^2^81
;;^UTILITY(U,$J,358.4,768,0)
;;=SPECIAL OPHTHALMIC SERVICES^4^81
;;^UTILITY(U,$J,358.4,769,0)
;;=ANTERIOR SEGMENT^2^82
;;^UTILITY(U,$J,358.4,770,0)
;;=GLAUCOMA^4^82
;;^UTILITY(U,$J,358.4,771,0)
;;=INFECTIONS^5^82
;;^UTILITY(U,$J,358.4,772,0)
;;=LENS/CATARACT^6^82
;;^UTILITY(U,$J,358.4,773,0)
;;=LOW VISION/BLINDNESS^7^82
;;^UTILITY(U,$J,358.4,774,0)
;;=DIABETES^3^82
;;^UTILITY(U,$J,358.4,775,0)
;;=MOST COMMON & POST OP^1^82
;;^UTILITY(U,$J,358.4,776,0)
;;=NEUROLOGIC EYE DISEASE^8^82
;;^UTILITY(U,$J,358.4,777,0)
;;=ORBIT/EYELID/LACRIMAL^9^82
;;^UTILITY(U,$J,358.4,778,0)
;;=REFRACTION^10^82
;;^UTILITY(U,$J,358.4,779,0)
;;=RETINA/VITREOUS^11^82
;;^UTILITY(U,$J,358.4,780,0)
;;=STRABISMUS^12^82
;;^UTILITY(U,$J,358.4,781,0)
;;=SYSTEMIC/TRAUMA/OTHER^13^82
;;^UTILITY(U,$J,358.4,782,0)
;;=NEW PATIENT^2^83
;;^UTILITY(U,$J,358.4,783,0)
;;=ESTABLISHED PATIENT^1^83
;;^UTILITY(U,$J,358.4,784,0)
;;=CONSULTATIONS^3^83
;;^UTILITY(U,$J,358.4,785,0)
;;=BIOPSY/DEBRIDEMENT^1^84
;;^UTILITY(U,$J,358.4,786,0)
;;=I&D/ASPIRATION^4^84
;;^UTILITY(U,$J,358.4,787,0)
;;=DESTRUCT-BENIGN/PREMALIG LESIONS^2^84
;;^UTILITY(U,$J,358.4,788,0)
;;=SCOPES^7^84
;;^UTILITY(U,$J,358.4,789,0)
;;=EXCISION^3^84
;;^UTILITY(U,$J,358.4,790,0)
;;=MISCELLANEOUS^5^84
;;^UTILITY(U,$J,358.4,791,0)
;;=PEG TUBE^6^84
;;^UTILITY(U,$J,358.4,792,0)
;;=UNNA BOOT^8^84
;;^UTILITY(U,$J,358.4,793,0)
;;=WOUND VAC DRESSING^9^84
;;^UTILITY(U,$J,358.4,794,0)
;;=ABDOMINAL PAIN^1^85
;;^UTILITY(U,$J,358.4,795,0)
;;=AFTERCARE POST SURGERY^2^85
;;^UTILITY(U,$J,358.4,796,0)
;;=BENIGN LESIONS OF SKIN^3^85
;;^UTILITY(U,$J,358.4,797,0)
;;=BREAST-FEMALE^5^85
;;^UTILITY(U,$J,358.4,798,0)
;;=BREAST-MALE^6^85
;;^UTILITY(U,$J,358.4,799,0)
;;=CARDIOVASCULAR^7^85
;;^UTILITY(U,$J,358.4,800,0)
;;=CIRRHOSIS^8^85
;;^UTILITY(U,$J,358.4,801,0)
;;=COLITIS^9^85
;;^UTILITY(U,$J,358.4,802,0)
;;=CROHN'S^10^85
;;^UTILITY(U,$J,358.4,803,0)
;;=DIVERTICULITIS^11^85
;;^UTILITY(U,$J,358.4,804,0)
;;=DIVERTICULOSIS^12^85
;;^UTILITY(U,$J,358.4,805,0)
;;=ENT^13^85
;;^UTILITY(U,$J,358.4,806,0)
;;=GANGLION^14^85
;;^UTILITY(U,$J,358.4,807,0)
;;=GANGRENE^15^85
;;^UTILITY(U,$J,358.4,808,0)
;;=GENERAL SIGNS/SYMPTOMS^16^85
;;^UTILITY(U,$J,358.4,809,0)
;;=GI^17^85
;;^UTILITY(U,$J,358.4,810,0)
;;=GYN^18^85
;;^UTILITY(U,$J,358.4,811,0)
;;=HEMORRHOIDS^19^85
;;^UTILITY(U,$J,358.4,812,0)
;;=INTESTINAL ABSCESS^20^85
;;^UTILITY(U,$J,358.4,813,0)
;;=LACERATION^21^85
;;^UTILITY(U,$J,358.4,814,0)
;;=MALIGNANT SKIN LESION^23^85
;;^UTILITY(U,$J,358.4,815,0)
;;=MELANOMA^24^85
;;^UTILITY(U,$J,358.4,816,0)
;;=MERKEL CELL CARCINOMA^25^85
--- Routine Detail --- with STRUCTURED ROUTINE LISTING ---[H[J[2J[HIBDEI3I7 3993 printed Dec 13, 2024@02:49:16 Page 2
IBDEI3I7 ; ; 19-NOV-2015
+1 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
+2 if 'DIFQR(358.4)
QUIT
FOR I=1:2
SET X=$TEXT(Q+I)
if X=""
QUIT
SET Y=$EXTRACT($TEXT(Q+I+1),4,999)
SET X=$EXTRACT(X,4,999)
if $ASCII(Y)=126
SET I=I+1
SET Y=$EXTRACT(Y,2,999)_$EXTRACT($TEXT(Q+I+1),5,99)
if $ASCII(Y)=61
SET Y=$EXTRACT(Y,2,999)
XECUTE NO
IF '$TEST
SET @X=Y
Q QUIT
+1 ;;^UTILITY(U,$J,358.4,751,0)
+2 ;;=INTRAVITREAL INJECTIONS^3^79
+3 ;;^UTILITY(U,$J,358.4,752,0)
+4 ;;=EDUCATION/COUNSELING^1^79
+5 ;;^UTILITY(U,$J,358.4,753,0)
+6 ;;=ANTERIOR SEGMENT^2^80
+7 ;;^UTILITY(U,$J,358.4,754,0)
+8 ;;=GLAUCOMA^4^80
+9 ;;^UTILITY(U,$J,358.4,755,0)
+10 ;;=INFECTIONS^5^80
+11 ;;^UTILITY(U,$J,358.4,756,0)
+12 ;;=LENS/CATARACT^6^80
+13 ;;^UTILITY(U,$J,358.4,757,0)
+14 ;;=LOW VISION/BLINDNESS^7^80
+15 ;;^UTILITY(U,$J,358.4,758,0)
+16 ;;=DIABETES^3^80
+17 ;;^UTILITY(U,$J,358.4,759,0)
+18 ;;=MOST COMMON & POST OP^1^80
+19 ;;^UTILITY(U,$J,358.4,760,0)
+20 ;;=NEUROLOGIC EYE DISEASE^8^80
+21 ;;^UTILITY(U,$J,358.4,761,0)
+22 ;;=ORBIT/EYELID/LACRIMAL^9^80
+23 ;;^UTILITY(U,$J,358.4,762,0)
+24 ;;=REFRACTION^10^80
+25 ;;^UTILITY(U,$J,358.4,763,0)
+26 ;;=RETINA/VITREOUS^11^80
+27 ;;^UTILITY(U,$J,358.4,764,0)
+28 ;;=STRABISMUS^12^80
+29 ;;^UTILITY(U,$J,358.4,765,0)
+30 ;;=SYSTEMIC/TRAUMA/OTHER^13^80
+31 ;;^UTILITY(U,$J,358.4,766,0)
+32 ;;=REFRACTION^1^81
+33 ;;^UTILITY(U,$J,358.4,767,0)
+34 ;;=GLASSES/CONTACT LENSES^2^81
+35 ;;^UTILITY(U,$J,358.4,768,0)
+36 ;;=SPECIAL OPHTHALMIC SERVICES^4^81
+37 ;;^UTILITY(U,$J,358.4,769,0)
+38 ;;=ANTERIOR SEGMENT^2^82
+39 ;;^UTILITY(U,$J,358.4,770,0)
+40 ;;=GLAUCOMA^4^82
+41 ;;^UTILITY(U,$J,358.4,771,0)
+42 ;;=INFECTIONS^5^82
+43 ;;^UTILITY(U,$J,358.4,772,0)
+44 ;;=LENS/CATARACT^6^82
+45 ;;^UTILITY(U,$J,358.4,773,0)
+46 ;;=LOW VISION/BLINDNESS^7^82
+47 ;;^UTILITY(U,$J,358.4,774,0)
+48 ;;=DIABETES^3^82
+49 ;;^UTILITY(U,$J,358.4,775,0)
+50 ;;=MOST COMMON & POST OP^1^82
+51 ;;^UTILITY(U,$J,358.4,776,0)
+52 ;;=NEUROLOGIC EYE DISEASE^8^82
+53 ;;^UTILITY(U,$J,358.4,777,0)
+54 ;;=ORBIT/EYELID/LACRIMAL^9^82
+55 ;;^UTILITY(U,$J,358.4,778,0)
+56 ;;=REFRACTION^10^82
+57 ;;^UTILITY(U,$J,358.4,779,0)
+58 ;;=RETINA/VITREOUS^11^82
+59 ;;^UTILITY(U,$J,358.4,780,0)
+60 ;;=STRABISMUS^12^82
+61 ;;^UTILITY(U,$J,358.4,781,0)
+62 ;;=SYSTEMIC/TRAUMA/OTHER^13^82
+63 ;;^UTILITY(U,$J,358.4,782,0)
+64 ;;=NEW PATIENT^2^83
+65 ;;^UTILITY(U,$J,358.4,783,0)
+66 ;;=ESTABLISHED PATIENT^1^83
+67 ;;^UTILITY(U,$J,358.4,784,0)
+68 ;;=CONSULTATIONS^3^83
+69 ;;^UTILITY(U,$J,358.4,785,0)
+70 ;;=BIOPSY/DEBRIDEMENT^1^84
+71 ;;^UTILITY(U,$J,358.4,786,0)
+72 ;;=I&D/ASPIRATION^4^84
+73 ;;^UTILITY(U,$J,358.4,787,0)
+74 ;;=DESTRUCT-BENIGN/PREMALIG LESIONS^2^84
+75 ;;^UTILITY(U,$J,358.4,788,0)
+76 ;;=SCOPES^7^84
+77 ;;^UTILITY(U,$J,358.4,789,0)
+78 ;;=EXCISION^3^84
+79 ;;^UTILITY(U,$J,358.4,790,0)
+80 ;;=MISCELLANEOUS^5^84
+81 ;;^UTILITY(U,$J,358.4,791,0)
+82 ;;=PEG TUBE^6^84
+83 ;;^UTILITY(U,$J,358.4,792,0)
+84 ;;=UNNA BOOT^8^84
+85 ;;^UTILITY(U,$J,358.4,793,0)
+86 ;;=WOUND VAC DRESSING^9^84
+87 ;;^UTILITY(U,$J,358.4,794,0)
+88 ;;=ABDOMINAL PAIN^1^85
+89 ;;^UTILITY(U,$J,358.4,795,0)
+90 ;;=AFTERCARE POST SURGERY^2^85
+91 ;;^UTILITY(U,$J,358.4,796,0)
+92 ;;=BENIGN LESIONS OF SKIN^3^85
+93 ;;^UTILITY(U,$J,358.4,797,0)
+94 ;;=BREAST-FEMALE^5^85
+95 ;;^UTILITY(U,$J,358.4,798,0)
+96 ;;=BREAST-MALE^6^85
+97 ;;^UTILITY(U,$J,358.4,799,0)
+98 ;;=CARDIOVASCULAR^7^85
+99 ;;^UTILITY(U,$J,358.4,800,0)
+100 ;;=CIRRHOSIS^8^85
+101 ;;^UTILITY(U,$J,358.4,801,0)
+102 ;;=COLITIS^9^85
+103 ;;^UTILITY(U,$J,358.4,802,0)
+104 ;;=CROHN'S^10^85
+105 ;;^UTILITY(U,$J,358.4,803,0)
+106 ;;=DIVERTICULITIS^11^85
+107 ;;^UTILITY(U,$J,358.4,804,0)
+108 ;;=DIVERTICULOSIS^12^85
+109 ;;^UTILITY(U,$J,358.4,805,0)
+110 ;;=ENT^13^85
+111 ;;^UTILITY(U,$J,358.4,806,0)
+112 ;;=GANGLION^14^85
+113 ;;^UTILITY(U,$J,358.4,807,0)
+114 ;;=GANGRENE^15^85
+115 ;;^UTILITY(U,$J,358.4,808,0)
+116 ;;=GENERAL SIGNS/SYMPTOMS^16^85
+117 ;;^UTILITY(U,$J,358.4,809,0)
+118 ;;=GI^17^85
+119 ;;^UTILITY(U,$J,358.4,810,0)
+120 ;;=GYN^18^85
+121 ;;^UTILITY(U,$J,358.4,811,0)
+122 ;;=HEMORRHOIDS^19^85
+123 ;;^UTILITY(U,$J,358.4,812,0)
+124 ;;=INTESTINAL ABSCESS^20^85
+125 ;;^UTILITY(U,$J,358.4,813,0)
+126 ;;=LACERATION^21^85
+127 ;;^UTILITY(U,$J,358.4,814,0)
+128 ;;=MALIGNANT SKIN LESION^23^85
+129 ;;^UTILITY(U,$J,358.4,815,0)
+130 ;;=MELANOMA^24^85
+131 ;;^UTILITY(U,$J,358.4,816,0)
+132 ;;=MERKEL CELL CARCINOMA^25^85
